News

Published on 8 Apr 2024 on Zacks via Yahoo Finance

Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick


Article preview image

One stock that might be an intriguing choice for investors right now is Alnylam Pharmaceuticals, Inc. ALNY. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 73 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.Meanwhile, Alnylam Pharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Alnylam Pharmaceuticals, Inc. Price and Consensus

Alnylam Pharmaceuticals, Inc. Price and ConsensusAlnylam Pharmaceuticals, Inc. Price and Consensus

NASDAQ.ALNY price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) just released its latest first-quarter results and th...

Simply Wall St. via Yahoo Finance 6 May 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript May 2, 2024 Alnylam ...

Insider Monkey via Yahoo Finance 4 May 2024

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) showcases robust revenue growth with a 54.8% increase i...

GuruFocus.com via Yahoo Finance 3 May 2024

Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y

Free Report) reported first-quarter 2024 adjusted loss of 16 cents per share, narrower than the...

Zacks 3 May 2024

Nucleic Acid-based Therapeutics Market to Reach USD 14.25 Billion by 2031 Driven by Surge in...

The demand for nucleic acid-based therapeutics has soared in recent years due to their effectiven...

Digital Journal 19 Apr 2024

Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick

One stock that might be an intriguing choice for investors right now is Alnylam Pharmaceuticals, ...

Zacks via Yahoo Finance 8 Apr 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard...

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standar...

Investing.com 7 Apr 2024

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript February 15, 2024 Al...

Insider Monkey via Yahoo Finance 16 Feb 2024

Alnylam stock sinks after last-minute changes in key drug trial - Boston Business Journal

Alnylam Pharmaceuticals Inc. saw its stock price sink to its lowest point in the last year after ...

The Business Journals 16 Feb 2024

Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%

Alnylam Pharmaceuticals ALNY reported a loss of $1.10 per share in the fourth quarter of 2023, na...

Zacks via Yahoo Finance 16 Feb 2024